Mabwell(SH:688062)2026-03-24 13:10Financial Performance - The company reported R&D expenses of CNY 976.96 million for the reporting period, an increase of 24.79% compared to the same period last year[3]. - The company raised a net amount of CNY 3,303.43 million during its IPO on the Shanghai Stock Exchange in January 2022[4]. - The company plans not to distribute cash dividends or issue new shares for the 2025 fiscal year due to accumulated losses of CNY -3,775.58 million in the parent company[12][13]. - The company's operating revenue for 2025 reached ¥662,515,554.62, a significant increase of 231.62% compared to ¥199,781,622.22 in 2024[32]. - The net loss attributable to shareholders decreased to ¥969,333,663.43 in 2025 from ¥1,043,919,217.28 in 2024, reflecting a reduction of ¥74,586,553.85[35]. - The sales revenue from pharmaceutical products amounted to ¥249,723,500, which is a 72.71% increase from ¥144,592,000 in the previous year[35]. - The cash flow from operating activities showed a net outflow of ¥290,223,166.42, which is an improvement compared to the outflow of ¥956,443,630.18 in 2024[32]. - The company's total assets increased by 6.56% to ¥4,555,842,397.99 at the end of 2025, compared to ¥4,275,508,853.05 in 2024[32]. - The net assets attributable to shareholders decreased by 77.72% compared to the previous year, primarily due to high R&D investments[36]. - The company reported a net profit attributable to shareholders of -¥969,223,418.62 for 2025, a slight improvement from -¥1,015,103,374.38 in 2024, but a decline from -¥935,228,300.47 in 2023[47]. Research and Development - The company has 14 key products in various stages of development, including 10 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases[3]. - The company anticipates continued high R&D expenditures in the coming years, with projected expenses of CNY 835.78 million, CNY 782.87 million, and CNY 976.96 million for 2023, 2024, and 2025, respectively[5]. - The company emphasizes the importance of clinical value in drug development, aligning with recent regulatory guidelines to ensure patient-centered outcomes[8]. - The company is investing in R&D for new therapies targeting autoimmune diseases, with a budget increase of 15% for the upcoming fiscal year[22]. - The company has developed and launched several monoclonal antibody injection products, including 9MW0311 (Mairishu®) and 9MW0321 (Mairuijian®)[20]. - The company is actively involved in the development of antibody-drug conjugates, including 9MW2821 (Bulumtatug Fuvedotin) and 9MW2921[20]. - The company has independently undertaken a major national project for new drug creation and is involved in multiple national key R&D programs, enhancing its innovation capabilities[57]. - The company has filed 69 new invention patent applications and received 18 new invention patent grants during the reporting period, bringing the total to 355 applications and 90 granted patents[57]. Product Development and Pipeline - The company has 4 products that have entered the commercialization stage, which is expected to improve its financial condition and help achieve profitability[4]. - The product pipeline includes a mix of preclinical, clinical research, and registered products, indicating a robust development strategy[58]. - The company is advancing its 9MW2821 (ADC) product for Nectin-4, with a mid-analysis expected in H2 2026 and Pre-NDA submission anticipated in the same period[60]. - The company has multiple ongoing clinical trials, including a Phase II trial for triple-negative breast cancer, expected to complete in 2024[60]. - The company is focusing on expanding its oncology pipeline, with several products in various stages of clinical trials, including esophageal cancer and lung cancer[60]. - The company is collaborating with multiple partners for its products, enhancing its market reach and development capabilities[60]. - The company is in the process of developing new therapies for various cancers, with a focus on innovative ADC technologies[60]. - The company is actively pursuing regulatory approvals for its pipeline products, indicating a robust strategy for future growth[60]. Market and Competitive Landscape - The global oncology drug market is projected to grow from $143.5 billion in 2019 to $253.3 billion by 2024, with a CAGR of 12.0%[177]. - The Chinese oncology drug market is expected to increase from $26.4 billion in 2019 to $35.9 billion by 2024, with a CAGR of 6.3%[177]. - The ADC market is anticipated to grow from $2.8 billion in 2019 to $14.1 billion by 2024, reflecting a CAGR of 37.9%[184]. - The Chinese ADC market is projected to expand from $500 million in 2024 to $1 billion in 2025, reaching $14.1 billion by 2032, with a CAGR of 45.9%[184]. - The market for RANKL monoclonal antibodies for treating giant cell tumor of bone (GCTB) is projected to grow from $1.049 billion in 2024 to $2.408 billion by 2028, with a CAGR of 23.1%[199]. - The market for RANKL monoclonal antibodies for osteoporosis treatment is expected to increase from $1.317 billion in 2024 to $4.694 billion by 2028, with a CAGR of 31.6%[199]. Regulatory and Compliance - The company is committed to maintaining compliance with cGMP standards to ensure the quality and safety of its products[22]. - The NHSA aims to implement a disease-based payment management system to enhance the efficiency of medical insurance fund payments and support high-quality development of medical institutions[174]. - The NHSA introduced a commercial health insurance directory for innovative drugs, including 19 high-priced innovative drugs, to support their development[174]. - The Ministry of Industry and Information Technology emphasized the need for the pharmaceutical industry to focus on innovation and enhance the resilience and safety of the pharmaceutical supply chain[175]. Strategic Partnerships and Collaborations - The company has established a partnership with Qilu Pharmaceutical in June 2025, with a contract value of up to 500 million RMB, including a non-refundable upfront payment of 380 million RMB[81]. - The company has signed formal cooperation agreements with 31 countries for 9MW0311 and submitted registration applications in eight countries, including Pakistan, which has already granted approval[70][71]. - The company has signed a strategic cooperation agreement with Ping An Good Doctor to create an integrated online and offline solution for bone health and autoimmune disease management, enhancing patient access to quality medical resources[162]. Challenges and Risks - The company has accumulated losses and will face potential risks, including reliance on external financing for operational cash flow, which may impact R&D and talent acquisition[4]. - The company faces risks related to the approval of its biosimilar product 9MW0813, which is currently under review and could impact sales revenue if not approved[6]. - The company is exposed to risks from centralized procurement policies that could lower the sales prices and gross margins of its biological products[7].